These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10821503)

  • 1. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count.
    Weinstein MH
    Hum Pathol; 2000 Apr; 31(4):520-1. PubMed ID: 10821503
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count.
    Lehr HA; Hansen DA; Kussick S; Li M; Hwang H; Krummenauer F; Trouet S; Gown AM
    Hum Pathol; 1999 Nov; 30(11):1314-20. PubMed ID: 10571511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
    Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
    Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
    Markiewski M; Domagała W
    Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma.
    Terasaki-Fukuzawa Y; Kijima H; Suto A; Takeshita T; Iezumi K; Sato S; Yoshida H; Sato T; Shimbori M; Shiina Y
    Int J Mol Med; 2002 Jan; 9(1):25-9. PubMed ID: 11744991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic relevance of estimates of proliferative activity in early breast cancer.
    Heatley MK; Maxwell P; Whiteside C; Ewing P; Toner PG
    Histopathology; 2005 Jan; 46(1):110-1. PubMed ID: 15656896
    [No Abstract]   [Full Text] [Related]  

  • 7. [Quantitative immunohistochemical tenascin test in infiltrative duct breast cancer].
    Zavalishina LE; Petrov AN; Andreeva IuIu
    Arkh Patol; 2005; 67(6):21-4. PubMed ID: 16405016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast.
    Hasebe T; Sasaki S; Imoto S; Ochiai A
    Mod Pathol; 2001 Apr; 14(4):325-37. PubMed ID: 11301349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preneoplasia of the breast.
    Böcker W
    Verh Dtsch Ges Pathol; 1997; 81():502-13. PubMed ID: 9474891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and Mitotic count on axillary lymph node metastasis in carcinoma breast.
    Pervez S; Khan MN; Nasir MI
    J Ayub Med Coll Abbottabad; 2007; 19(1):3-5. PubMed ID: 17867469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
    Keshgegian AA; Cnaan A
    Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic counts provide additional prognostic information in grade II mammary carcinoma.
    Lynch J; Pattekar R; Barnes DM; Hanby AM; Camplejohn RS; Ryder K; Gillett CE
    J Pathol; 2002 Mar; 196(3):275-9. PubMed ID: 11857489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer.
    Hoque A; Menter DG; Sahin AA; Sneige N; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):153-4. PubMed ID: 11219775
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of double staining of MIB-1 and AgNORs in primary breast carcinoma.
    Kidogawa H; Nanashima A; Yano H; Matsumoto M; Yasutake T; Nagayasu T
    Anticancer Res; 2005; 25(6B):3957-62. PubMed ID: 16309183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
    Masiuk M
    Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is breast tumor progression really linear?
    Polyak K
    Clin Cancer Res; 2008 Jan; 14(2):339-41. PubMed ID: 18223205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.